Abstract
Post COVID 19 Lung Parenchymal Disease Management Experience with Follow up Outcomes in Qatar: A Case Series
Phool Iqbal*, Muhammad Bilal Jamshaid, Aamir Shahzad, Zohaib Yousaf, Saba Nabavi Monfared, Nagham D Sadik and Ibrahim Fawzy Hassa
Corresponding Author: Phool Iqbal, Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar.
Revised: November 11, 2021; Available Online: November 11, 2021
Citation: Iqbal P, Jamshaid MB, Shahzad A, Yousaf Z, Monfared SN, et al. (2021) Post COVID 19 Lung Parenchymal Disease Management Experience with Follow up Outcomes in Qatar: A Case Series. BioMed Res J, 5(S2): 05.
Copyrights: ©2021 Iqbal P, Jamshaid MB, Shahzad A, Yousaf Z, Monfared SN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share :
  • 71

    Views & Citations
Background: COVID 19 has resulted in one of the worst global pandemics in recent history. Post-COVID 19 interstitial lung disease is a significant concern in COVID-19 survivors. It is a disabling clinical condition for the patients and a burden on the healthcare system. With the passage of time and subsequent different waves of COVID 19 across the globe, post-COVID 19 sequelae of lung diseases can be debilitating.

Case Series: We report case series of three patients with persistent hypoxia post-COVID 19, raising concerns for interstitial lung disease in Qatar. We shared our experience of the patient's clinical course, complications, and outcomes in post-COVID 19 sequelae of lung parenchymal disease.

Results: The patients were followed up during and after treatment until recovery or discharge from the hospital.

Conclusion: Through our case series, we want to highlight few points. First, the approach and management strategy of post-COVID 19 lung parenchymal disease patients is individualized. Sequelae of Post COVID 19 interstitial lung diseases do not follow the same course during the follow-up period, and outcomes may differ. Two different entities are reported with regards to post-COVID 19 lung parenchymal disease. Post-COVID 19 fibrotic lung disease and fibrotic-like lesions follow different clinical courses, management strategies, and outcomes. Therefore, further studies for categorization of post-COVID 19 lungs parenchymal disease and adequate follow-up at regular time intervals are required.

Keywords: Post COVID 19, Lung fibrosis, ICU, Anti-fibrotic, Pulmonary rehabilitation